Renaissance Capital logo

Vivos Therapeutics Priced, Nasdaq: VVOS

Commercializing non-invasive medical devices for sleep disordered breathing.

Industry: Health Care

First Day Return: +49.8%

We are a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We offer novel and proprietary alternatives for treating mild-to-moderate OSA as well as certain craniofacial and anatomical anomalies known to be associated with mild-to-moderate OSA. We believe our products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (or CPAP). Our treatment for mild-to-moderate OSA involves specially designed and customized oral appliances and treatment protocols that we call the Vivos System. We believe the Vivos System technology represents the first non-surgical, non-invasive and cost-effective solution that normally does not require lifetime use or intervention for the hundreds of millions of people globally who suffer from mild-to-moderate OSA.

Vivos Therapeutics (VVOS) Performance

Created with Highcharts 10.3.2Chart context menuVVOS vs. IPO Index (IPOUSA)Jan '21Apr '21Jul '21Oct '21Jan '22Apr '22Jul '22Oct '22Jan '23Apr '23Jul '23Oct '23Jan '24Apr '24Jul '24Oct '24Jan '25-50%0%-100%+ 50%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index